Alembic Pharmaceuticals has posted small growth of 7.2 per cent in consolidated profit during the third quarter ended December 2014 to Rs. 70.66 crore from Rs. 65.93 crore in the similar quarter of last year. EBDITA remained stagnant at Rs. 103 crore. Its consolidated net sales also moved up only by 3.2 per cent to Rs. 510.95 crore from Rs. 494.87 crore. EPS worked out to Rs. 3.75 as against Rs. 3.50 in the last period. Alembic scrip declined sharply by over Rs. 57, after the announcement of financial working, to Rs. 425.25 on BSE.

The India branded formulations business posted sales of Rs. 250 crore against Rs. 225.1 crore and specialty and acute segments grew by 19 per cent and 3 per cent respectively in the current quarter. International generic formulation posted growth of 3 per cent to Rs. 133.3 crore as compared to Rs. 129.6 crore over the corresponding quarter of last year.

The company filed one ANDA application taking cumulative ANDA filings of the company to 66. It received one ANDA approval and total approval reached at 36 ANDAs. It also filed 2 DMF applications, taking cumulative DMF filings to 70.

For the nine months ended December 2014, its consolidated net sales increased by 11 per cent to Rs. 1,551 crore from Rs. 1,397 crore in the same period of last year. Its net profit went up by 22 per cent to Rs. 212 crore from Rs. 174 crore. EPS improved to Rs. 11.28 from Rs. 9.24. Its Indian formulation sales increased by 15 per cent to Rs. 749 crore from Rs. 651 crore. However, Indian generic sales declined marginally by 2 per cent to Rs. 91 crore from Rs. 92 crore. The sales of international branded declined by 3 per cent to Rs. 54 crore from Rs. 56 crore and that of International generic went up by 13 per cent to Rs. 371 crore from Rs. 329 crore. API sales increased by 8 per cent to Rs. 281 crore from Rs. 261 crore.